Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Greil

Showing results (11-20 of 525) with videos related to

Pageof 53
Sort By:
Haematologica|November 2, 2015
Response to comment by P. Vassilakopoulos and colleaguesUlrich Jaeger, Michael Praxmarer, Richard Greil, et al.
British Journal of Haematology|May 19, 2020
IDO in MDS/AML disease progression and its role in resistance to azacitidine: a potential new drug target?Michael Leisch, Richard Greil, Lisa Pleyer
Current Cancer Drug Targets|January 11, 2021
Re-Sensitizing Tumor Cells to Cancer Drugs with Epigenetic RegulatorsStefanie Rauscher, Richard Greil, Roland Geisberger
International Journal of Molecular Sciences|June 30, 2016
Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?Lisa Pleyer, Peter Valent, Richard Greil
Oncoscience|November 22, 2018
Risks and chances of aberrant DNA repair in cancerMaria Schubert, Richard Greil, Roland Geisberger
Future Oncology (London, England)|August 17, 2018
Plitidepsin: a potential new treatment for relapsed/refractory multiple myelomaMichael Leisch, Alexander Egle, Richard Greil
Memo|September 18, 2018
SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosisGabriel Rinnerthaler, Simon Peter Gampenrieder, Richard Greil
Expert Review of Anti-Infective Therapy|December 18, 2012
What paths are open for tackling increasing azole resistance in Aspergillus in the clinic?Jutta Auberger, Richard Greil, Cornelia Lass-Flörl
International Journal of Molecular Sciences|March 8, 2019
HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast CancerGabriel Rinnerthaler, Simon Peter Gampenrieder, Richard Greil
Journal of Oncology|September 13, 2013
Neoadjuvant chemotherapy and targeted therapy in breast cancer: past, present, and futureSimon P Gampenrieder, Gabriel Rinnerthaler, Richard Greil
Pageof 53

Showing results (11-20 of 525) with videos related to

Sort By:
Pageof 53
Haematologica|November 2, 2015
Response to comment by P. Vassilakopoulos and colleaguesUlrich Jaeger, Michael Praxmarer, Richard Greil, et al.
British Journal of Haematology|May 19, 2020
IDO in MDS/AML disease progression and its role in resistance to azacitidine: a potential new drug target?Michael Leisch, Richard Greil, Lisa Pleyer
Current Cancer Drug Targets|January 11, 2021
Re-Sensitizing Tumor Cells to Cancer Drugs with Epigenetic RegulatorsStefanie Rauscher, Richard Greil, Roland Geisberger
International Journal of Molecular Sciences|June 30, 2016
Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?Lisa Pleyer, Peter Valent, Richard Greil
Oncoscience|November 22, 2018
Risks and chances of aberrant DNA repair in cancerMaria Schubert, Richard Greil, Roland Geisberger
Future Oncology (London, England)|August 17, 2018
Plitidepsin: a potential new treatment for relapsed/refractory multiple myelomaMichael Leisch, Alexander Egle, Richard Greil
Memo|September 18, 2018
SABCS 2017: lifestyle factors, hormone receptor-positive advanced disease, liquid biopsies, and prognosisGabriel Rinnerthaler, Simon Peter Gampenrieder, Richard Greil
Expert Review of Anti-Infective Therapy|December 18, 2012
What paths are open for tackling increasing azole resistance in Aspergillus in the clinic?Jutta Auberger, Richard Greil, Cornelia Lass-Flörl
International Journal of Molecular Sciences|March 8, 2019
HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast CancerGabriel Rinnerthaler, Simon Peter Gampenrieder, Richard Greil
Journal of Oncology|September 13, 2013
Neoadjuvant chemotherapy and targeted therapy in breast cancer: past, present, and futureSimon P Gampenrieder, Gabriel Rinnerthaler, Richard Greil
Pageof 53